- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Photocure (PHO)
Photocure stock price live, this page displays OL PHO stock exchange data. View the PHO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Photocure real time stock price chart below.
What Is the Photocure Stock Price Today?
The Photocure stock price today is 47,50.
What Is the Stock Symbol for Photocure?
The stock symbol for Photocure is "PHO."
What Stock Exchange Does Photocure Trade On?
Photocure is listed and trades on the Oslo stock exchange.
Is Photocure a Good Stock to Buy?
Determining whether Photocure—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHO quote. (ISIN: NO0010000045)
What Is the Photocure Stock Price Today?
The Photocure stock price today is 47,50.
What Is the Stock Symbol for Photocure?
The stock symbol for Photocure is "PHO."
What Stock Exchange Does Photocure Trade On?
Photocure is listed and trades on the Oslo stock exchange.
Is Photocure a Good Stock to Buy?
Determining whether Photocure—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHO quote. (ISIN: NO0010000045)
Currency in NOK
47.50
-2.50(-5.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
47.20
50.70
52 wk Range
46.25
79.80
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
47.2050.70
52 wk Range
46.2579.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
78.00
Upside
+64.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 78.00
(+64.21% Upside)
Photocure Earnings Call Summary for Q3/2026
- Q3 revenue rose to NOK 140.9M from NOK 135M YoY; Hexvix/Cysview product revenue up 7% at constant currency to NOK 134.2M despite shares falling 4.9%.
- Gross margin improved to 93% from 92%; adjusted EBITDA of NOK 18.5M with 11% margin, though net loss reached NOK 26.2M amid rising operating expenses.
- Company raised 2026 product revenue growth guidance to 10-12%; projects consolidated revenue growth exceeding 25% annually through 2030.
- North American active accounts grew 20% YoY to 454; ForTec mobile fleet expanded to 31 towers from 24, now representing 19% of regional business.
- Management prioritizes AssureMDx Medicare coverage via Novitas LCD pathway; expects next-gen flexible cystoscopy launch-ready by end-2027 and FDA reclassification decision.
Last Updated: 2026/10/28, 16:02
Read Full TranscriptEarnings
Latest Release
Jul 29, 2026
EPS / Forecast
-0,03 / --
Revenue / Forecast
142,48M / 137M
Compare PHO to Peers and Sector
Metrics to compare | PHO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 16.2x | 14.8x | −0.3x | |
PEG Ratio | 0.01 | 0.00 | 0.00 | |
Price/Book | 2.1x | 1.9x | 2.6x | |
Price / LTM Sales | 1.9x | 1.1x | 2.9x | |
Upside (Analyst Target) | 64.2% | 31.4% | 64.0% | |
Fair Value Upside | Unlock | −7.8% | 9.7% | Unlock |
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf’s System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. It has partnership with Artera for digital pathology AI test evaluation for bladder cancer. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, other European countries, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Photocure (PHO) Stock Price Today?
The Photocure stock price today is 47,50 NOK.
What Stock Exchange Does Photocure Trade On?
Photocure is listed and trades on the Oslo Stock Exchange.
What Is the Stock Symbol for Photocure?
The stock symbol for Photocure is "PHO."
What Is the Photocure Market Cap?
As of today, Photocure market cap is 1,28B NOK.
What Is Photocure's Earnings Per Share (TTM)?
The Photocure EPS (TTM) is 2,94.
When Is the Next Photocure Earnings Date?
Photocure will release its next earnings report on Oct 28, 2026.
From a Technical Analysis Perspective, Is PHO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Photocure Stock Split?
Photocure has split 1 times.
How Many Employees Does Photocure Have?
Photocure has 100 employees.
What is the current trading status of Photocure (PHO)?
As of Oct 28, 2026, Photocure (PHO) is trading at a price of 47,50 NOK, with a previous close of 47,50 NOK. The stock has fluctuated within a day range of 47,20 NOK to 50,70 NOK, while its 52-week range spans from 46,25 NOK to 79,80 NOK.
What Is Photocure (PHO) Price Target According to Analysts?
The average 12-month price target for Photocure is 78,00 NOK, with a high estimate of 85 NOK and a low estimate of 70 NOK. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +64,21% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.